Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Boehringer Ingelheim Selects Certara’s D360 as its Global Drug Discovery Platform
October 17, 2013
D360™ will permit chemical structure and related biological property data to be shared between global sites.
ST. LOUIS, MO – Oct. 17, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that the pharmaceutical company Boehringer Ingelheim has chosen D360 as its global drug discovery platform. Certara’s D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data. D360 will allow Boehringer Ingelheim to share discovery data across global working groups that can include external collaborators.
Boehringer Ingelheim plans to install the global data mining tool at three of its sites, located in Ridgefield, CT; Biberach, Germany; and Vienna, Austria. All of the sites are currently using different data sources, mining tools, and workflows for analyzing the information.
“In addition to integrating data for easy access, D360 empowers researchers to query and analyze their data without support from the IT team,” said Jonathan Feldmann, vice president of scientific informatics at Certara. “D360 enables researchers to quickly answer their questions as they conceive them, thus helping to shorten the drug discovery cycle.”
About Certara
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit http://www.certara.com.
Certara Contact:
Diana O’Rourke, 314-951-3310
Director of Marketing
diana.orourke@certara.com
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com